Operating mechanism

The invention and the patent linked to the product, Procont, are about studying a protein that affects the P53 enzyme and the production of the P53 enzyme itself. These proteins are extracted from a specific biological system that increases the level of the P53 enzyme in the cell, in the nucleus, so that it can eliminate DNA sequence errors during division. And once division has taken place, it can cut off this process, so that programmed cell death – apoptosis – takes place.

Tumour cells multiply at an unimaginable rate: but this can be inhibited by the right levels of the enzyme P53, which is present in all our cells. When the body is supplied with this protein, it helps the enzyme to function at the right level, and even stimulates it. In fact, it regulates cell division and reduces the number of tumour cells, which is why Procont Plus can be used as a complementary therapy to conventional Western chemotherapy and radiotherapy.

The two methods (conventional – chemo-/radiotherapy and alternative therapy) are not mutually exclusive. Procont Plus facilitates rather than suppresses the effects of chemotherapy. There is no interaction, no point of conflict where the two treatments can reduce each other’s effects. Most importantly, Procont Plus has virtually no side effects.

Patent

Procont Plus dietary supplement capsules contain an immunoactive active ingredient derived from a biological system with an international patent-protected technology, with general anti-tumour activity. It acts at the cell division phase, namely through the tumour suppressor gene: maintaining its physiological level, it detects transcription defects in the cell division process and immediately destroys the defective (tumour) cell that has not yet divided. The patent holder behind the active substance is Dr Bertha András, experimental toxicologist, pharmacologist-pharmacologist. The patent was assigned international patent number PCT/HU0300004 on 15 January 2003, P0200172.